Too much intake of Salt in teenage can increase risk of stroke later | WeForNews | Latest News, Blogs Too much intake of Salt in teenage can increase risk of stroke later – WeForNews | Latest News, Blogs
Connect with us

Health

Too much intake of Salt in teenage can increase risk of stroke later

Published

on

Teenage Girls

According to recent study, too much intake of salt in adolescents’ diet may adversely affect their blood vessels, increasing the risk for cardiovascular diseases such as heart attack and stroke, during adulthood.

Too much salt caused measurable changes in their blood vessels that led to arterial stiffness, or hardening of the arteries — early signs of cardiovascular disease.

Further, higher average daily sodium intake was associated with lower brachial artery (BrachD), located in the upper arm and higher pulse wave velocity (PWV).

Both these readings indicate higher levels of stiffness in both peripheral arteries in the extremities, as well as in central arteries, tied to higher sodium consumption.

“Our study suggests adolescents and young adults with higher-than-recommended amounts of salt in their diet may translate into changes in the body that put them at higher risk for future heart attack and stroke,” said Elaine M. Urbina, Director at Cincinnati Children’s Hospital Medical Centre in Ohio, US.

The findings were presented at the 2017 Pediatric Academic Societies Meeting in San Francisco.

For the study, the team involved 775 participants who were measured for the elasticity or distensibility of their brachial artery (BrachD), located in the upper arm.

Pulse wave velocity (PWV) was also measured for differences in the speed that blood travelled between their carotid artery in the neck and femoral artery in the groin.

The amount of sodium they consumed was measured with self-reported, three-day diet records.

(IANS)

Disaster

‘Situation going out of control’: SC seeks Covid report from Delhi, Gujarat, Maharashtra and Assam

A bench headed by Justice Ashok Bhushan said the infections in these states are “going out of control” and asked them to submit a status report within two days.

Published

on

Coronavirus India

The Supreme Court on Monday sought a status report from Delhi, Gujarat, Maharashtra, and Assam on steps taken to control the spread of coronavirus infection, news agency PTI reported. A bench headed by Justice Ashok Bhushan said the infections in these states are “going out of control” and asked them to submit a status report within two days.

“Things have worsened in Delhi especially in November. You file a status report on what steps have been taken,”the court told Additional Solicitor General Sanjay Jain, who was appearing for the Delhi government. The bench, also comprising Justices R S Reddy and M R Shah, said that all efforts shall be made by the Centre and the states to mitigate the situation and to deal with the rising number of COVID-19 cases.

While fresh cases of coronavirus infections continue to decline — or remain stagnant — in the worst-affected states of Maharashtra, Karnataka, and Andhra Pradesh, on the other hand, Haryana, Punjab, Rajasthan, Gujarat, Madhya Pradesh and even Himachal Pradesh have been seeing a significant rise in active cases.

Amid the surge in a few states, the Centre on Sunday dispatched high-level teams to Uttar Pradesh, Punjab and Himachal Pradesh to help them tackle the spread of the disease. A few days ago, similar teams were sent to Rajasthan, Gujarat, Haryana and Chhattisgarh as well.

Part of the reason for the surge in cases in these states could be attributed to low adherence of physical distancing norms during the festival season, especially since it came after a prolonged phase of relative stability, which could have given rise to complacency amongst the public.

On Monday, India’s COVID-19 caseload went past 91 lakh with 44,059 coronavirus infections being reported in a day, while the recoveries surged to 85,62,641. The number of active cases remained below 5 lakh for the thirteenth consecutive day. There are 4,43,486 active cases of coronavirus infection in the country as on date which comprises 4.85 per cent of the total caseload.

Continue Reading

Health

Covid-19: Govt may get Oxford shots in Jan-Feb, at 50% of MRP

The SII has almost completed its phase 3 trials in India and a follow-up of the data is likely to start soon.

Published

on

Vaccine

NEW DELHI: India is likely to get the first lot of anti-Covid shots in late January-early February which will allow some frontline workers like doctors, nurses and municipal staff to get the vaccine. This will be possible as India plans to give Serum Institute of India (SII) emergency use approval for the Oxford-AstraZeneca vaccine candidate soon after it gets similar approval in the UK.

While the SII will need to apply for emergency use, the firm is expected to do so in December. The Centre is finalising a contract with vaccine manufacturers for procurement of doses. The government, which will make bulk purchases, has also negotiated a better price — almost half that of the likely MRP of Rs 500-600 for the two-shot vaccine, an official source said.

Bharat Biotech’s Covaxin can be considered for emergency approval after it submits data from phase I and II trials. Regulatory sources told TOI that Bharat Biotech is in the process of publishing data for the vaccine which is now in phase 3 trials in India. So, two vaccines could be available by February.

“If everything goes as per plan and the company (SII) manages to secure emergency authorisation in December, we are expecting the first lot of vaccines by January-February and the first set of beneficiaries has been identified,” the official said.

While an estimated 50-60 crore doses will be required to inoculate 25-30 crore priority population categorised into four different groups, initially limited stocks are expected by January-end that will be administered mainly to some of the estimated 70 lakh healthcare professionals and over 2 crore frontline workers including police, municipal workers and armed forces.

The SII has almost completed its phase 3 trials in India and a follow-up of the data is likely to start soon.

“If Serum Institute submits its efficacy data from UK and applies for emergency authorisation here, it can easily be granted. But even in case of Bharat Biotech, if the company applies for emergency use approval after its data from phase 1 and 2 are published, the regulator can consider the same,” the official said, indicating that by February-March, more than one vaccine is likely to get at least emergency use authorisation provided the regulator finds data generated from clinical trials satisfactory.

Meanwhile, government is framing terms of references for two major bodies dealing with vaccine introduction — the National Technical Advisory Group on Immunisation and the Central Drug Standards and Control Organisation — to look into grant of emergency authorisation.

Continue Reading

Health

Renowned cardiologist Dr Bansal opens SSB Heart and Multispecialty Hospital in Faridabad

SSB Heart and Multispecialty Hospital which was formally known as ORG Central Hospital near Neelam Flyover, Sector 20A, Faridabad (Delhi-NCR).

Published

on

SSB Heart Dr Bansal

Renowned cardiologist Dr. S.S. Bansal opens SSB Heart and Multispecialty Hospital in Faridabad.

NCR patients requiring heart monitoring and diagnostics can now have a sign of relief as Renowned cardiologist Dr. S.S. Bansal has opened his own hospital.

Dr. Bansal and his entire expert team including Sr. Heart Surgeon, Dr. Sudeep Singh Sidhu has stared the new hospital in the name of SSB Heart and Multispecialty Hospital which was formally known as ORG Central Hospital near Neelam Flyover, Sector 20A, Faridabad (Delhi-NCR).

Dr. Bansal and his whole team including Sr. Heart Surgeon, Dr. Sundeep Sidhu has moved from Metro Hospital Faridabad.

For appointment of Dr. SS Bansal and Dr. Sudeep Singh Sidhu, please contact Mr. Nishant at +91-7669990182.

SSB Heart Dr Bansal Faridabad
Continue Reading
Advertisement

Most Popular

Corona Virus (COVID-19) Live Data

COVID-19 affects different people in different ways. Most infected people will develop mild to moderate illness and recover without hospitalization.